1. Home
  2. AGBK vs SLDB Comparison

AGBK vs SLDB Comparison

Compare AGBK & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AGI Inc Class A Common Shares

AGBK

AGI Inc Class A Common Shares

N/A

Current Price

$5.88

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$7.28

Market Cap

932.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGBK
SLDB
Founded
1999
2013
Country
Brazil
United States
Employees
N/A
121
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
932.9M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
AGBK
SLDB
Price
$5.88
$7.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
★ $17.20
$16.36
AVG Volume (30 Days)
155.2K
★ 948.7K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 34.97
EPS
★ N/A
N/A
Revenue
N/A
★ $8,094,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$235.22
N/A
P/E Ratio
$46.19
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$5.73
$3.79
52 Week High
$12.21
$11.45

Technical Indicators

Market Signals
Indicator
AGBK
SLDB
Relative Strength Index (RSI) 32.42 30.15
Support Level N/A $6.38
Resistance Level $7.42 $8.12
Average True Range (ATR) 0.21 0.50
MACD -0.07 -0.22
Stochastic Oscillator 10.14 4.93

Price Performance

Historical Comparison
AGBK
SLDB

About AGBK AGI Inc Class A Common Shares

AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: